EXGMUBM
Market cap18mUSD
Dec 23, Last price
0.82EUR
1D
6.79%
1Q
-8.09%
IPO
-79.80%
Name
Ulisse Biomed Spa
Chart & Performance
P/E
—
P/S
272.19
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.37%
Rev. gr., 5y
287.27%
Revenues
66k
-52.17%
Net income
-5m
L+266.80%
CFO
-1m
L+42.76%
Profile
Ulisse Biomed S.p.A., a healthcare biotech company, provides diagnostic platforms and products. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It also provides various tests and reagents for sexually transmitted diseases and HPV for oropharyngeal cancer. In addition, the company's platforms also comprise NanoHybrid, a DNA/PNA based multi-modal biomolecule platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. Ulisse Biomed S.p.A. was founded in 2015 and is based in Udine, Italy.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 66 -52.17% | 138 -49.96% | 277 -35.52% | |||
Cost of revenue | 2,916 | 2,187 | 1,177 | |||
Unusual Expense (Income) | ||||||
NOPBT | (2,849) | (2,049) | (901) | |||
NOPBT Margin | ||||||
Operating Taxes | 1 | |||||
Tax Rate | ||||||
NOPAT | (2,849) | (2,049) | (901) | |||
Net income | (4,797) 266.80% | (1,308) 116.66% | (604) -371.89% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 42 | 2 | 6,297 | |||
BB yield | 0.00% | -0.03% | -23.48% | |||
| Debt | ||||||
Debt current | 82 | 7 | 3 | |||
Long-term debt | 415 | |||||
Deferred revenue | 298 | 397 | ||||
Other long-term liabilities | 1,275 | 16 | 9 | |||
Net debt | (2,297) | (3,792) | (5,014) | |||
| Cash flow | ||||||
Cash from operating activities | (1,385) | (970) | (395) | |||
CAPEX | (99) | (228) | (956) | |||
Cash from investing activities | (98) | (228) | (958) | |||
Cash from financing activities | 42 | 2 | 6,299 | |||
FCF | (5,094) | (2,064) | (2,112) | |||
| Balance | ||||||
Cash | 2,788 | 3,794 | 4,990 | |||
Long term investments | 6 | 6 | 27 | |||
Excess cash | 2,791 | 3,793 | 5,003 | |||
Stockholders' equity | (9,934) | (5,272) | (3,965) | |||
Invested Capital | 39,056 | 11,511 | 11,609 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 21,570 | 8,065 | 8,064 | |||
Price | 1.66 63.06% | 1.02 -69.38% | 3.33 | |||
Market cap | 35,806 336.14% | 8,210 -69.38% | 26,812 | |||
EV | 33,509 | 4,417 | 21,798 | |||
EBITDA | (2,519) | (1,729) | (653) | |||
EV/EBITDA | ||||||
Interest | 139 | 164 | 206 | |||
Interest/NOPBT | ||||||